Spruce Biosciences Inc (SPRB) Stock Price, Quote & News

Company Profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, includ...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 655 4168

Website: sprucebio.com

Address:

611 Gateway Boulevard, Suite 740, South San Francisco, United States

TheGodsMustBeCrazy Mar. 20 at 9:20 PM

$SPRB Tonight's SEC filing is meaningless. It's in reference to a drug that is NOT sprb's lead drug.

0 · Reply

FilingTracker Mar. 20 at 9:07 PM

$SPRB Terminated agreement with Kaken Pharmaceutical Co., Ltd.: https://www.sec.gov/Archives/edgar/data/1683553/000119312526117888/sprb-20260316.htm

0 · Reply

Midori_Hachi Mar. 18 at 4:39 PM

$SPRB

0 · Reply

BladeKingShadowLordX Mar. 16 at 11:18 PM

$ALDX HAHA sHrekli ! U pumped dog $SPRB now it's my TURD Watch me PUMp this BABy

0 · Reply

RickyIsRich Mar. 16 at 3:12 PM

$SPRB wonderful drug FDA Q4 2026 potential $500 stock slam dunk buying

1 · Reply

Jakcofalltrades Mar. 16 at 2:28 AM

$SPRB who’s buying this shit

0 · Reply

History101 Mar. 9 at 10:29 PM

$SPRB 4,993 watching 3/9/2026

0 · Reply

ShakeThatMoneyMaker Mar. 9 at 3:40 PM

$SPRB sold my 1k shares here at 61. Took a fat loss here but Im not sticking around for another 1M shares of dilution. Current float prior to this was only 1.1M. Gotta admit when you are wrong sometimes

3 · Reply

FilingTracker Mar. 9 at 11:34 AM

$SPRB Offering - up to $75 million: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097569/sprb-424b5-2026.htm

0 · Reply

BillionerOfKing Mar. 2 at 11:05 PM

$SPRB Current Stock Price: $54.27

0 · Reply

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Mar 9, 2026, 7:00 AM EDT - 12 days ago

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Mar 2, 2026, 4:05 PM EST - 19 days ago

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Feb 18, 2026, 7:00 AM EST - 4 weeks ago

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Feb 17, 2026, 4:05 PM EST - 4 weeks ago

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 5, 2026, 4:05 PM EST - 6 weeks ago

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Feb 3, 2026, 8:00 AM EST - 6 weeks ago

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Jan 28, 2026, 8:00 AM EST - 7 weeks ago

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Jan 18, 2026, 7:02 PM EST - 2 months ago

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Jan 8, 2026, 8:00 AM EST - 2 months ago

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Dec 15, 2025, 8:00 AM EST - 3 months ago

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Nov 10, 2025, 4:05 PM EST - 4 months ago

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Oct 7, 2025, 10:38 AM EDT - 5 months ago

Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)

Oct 7, 2025, 9:44 AM EDT - 5 months ago

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Oct 6, 2025, 8:00 AM EDT - 5 months ago

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Sep 15, 2025, 7:00 AM EDT - 6 months ago

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

TheGodsMustBeCrazy Mar. 20 at 9:20 PM

$SPRB Tonight's SEC filing is meaningless. It's in reference to a drug that is NOT sprb's lead drug.

0 · Reply

FilingTracker Mar. 20 at 9:07 PM

$SPRB Terminated agreement with Kaken Pharmaceutical Co., Ltd.: https://www.sec.gov/Archives/edgar/data/1683553/000119312526117888/sprb-20260316.htm

0 · Reply

Midori_Hachi Mar. 18 at 4:39 PM

$SPRB

0 · Reply

BladeKingShadowLordX Mar. 16 at 11:18 PM

$ALDX HAHA sHrekli ! U pumped dog $SPRB now it's my TURD Watch me PUMp this BABy

0 · Reply

RickyIsRich Mar. 16 at 3:12 PM

$SPRB wonderful drug FDA Q4 2026 potential $500 stock slam dunk buying

1 · Reply

Jakcofalltrades Mar. 16 at 2:28 AM

$SPRB who’s buying this shit

0 · Reply

History101 Mar. 9 at 10:29 PM

$SPRB 4,993 watching 3/9/2026

0 · Reply

ShakeThatMoneyMaker Mar. 9 at 3:40 PM

3 · Reply

FilingTracker Mar. 9 at 11:34 AM

$SPRB Offering - up to $75 million: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097569/sprb-424b5-2026.htm

0 · Reply

BillionerOfKing Mar. 2 at 11:05 PM

$SPRB Current Stock Price: $54.27

0 · Reply

BioTechHealthX Mar. 1 at 3:16 PM

$SPRB Spruce Biosciences (NASDAQ: SPRB) just gained key FDA clarity ahead of its planned BLA submission for tralesinidase alfa. With accelerated approval potential, orphan drug upside, and rare pediatric disease incentives back in play, could this small-cap biotech stock be setting up for a major re-rating? https://biotechhealthx.com/biotech-news/is-it-a-great-choice-to-buy-spruce-biosciences-sprb-shares/

0 · Reply

Benalish Feb. 23 at 3:09 AM

$SPRB

0 · Reply

PortfolioObelisk Feb. 20 at 2:04 PM

$SPRB Spruce Biosciences develops endocrine therapies. Clinical validation drives valuation. Early-stage risk remains high.

0 · Reply

ILuvbiotech Feb. 20 at 5:24 AM

$SPRB Many people became millionaires holding this, the next runner is $NWBO

3 · Reply

OfficialStocktwitsUser Feb. 20 at 12:45 AM

$SPRB RSI: 29.11, MACD: -5.7053 Vol: 10.30, MA20: 75.80, MA50: 79.01 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

theflynews Feb. 19 at 5:06 PM

Biotech Alert: Searches spiking for these stocks today - $SPRB - https://legacy.thefly.com/permalinks/entry.php/id4296596

0 · Reply

TheBasedTrader Feb. 19 at 4:14 PM

$SPRB one last major bullet going in. +300 shares totaling 600.

0 · Reply

ErikTon Feb. 19 at 2:39 PM

$SPRB going to 45$

0 · Reply

Benalish Feb. 19 at 2:11 PM

$SPRB HC Wainwright drops PT by 10% exactly how much it should have dropped, not 40% lol

0 · Reply

DARKP00L Feb. 19 at 12:20 PM

$SPRB 07:14 on Feb. 19 2026 HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $200 #tradeideas

0 · Reply

Benalish Feb. 19 at 4:01 AM

$SPRB

0 · Reply

Benalish Feb. 19 at 3:26 AM

$SPRB https://finance.yahoo.com/news/coty-downgraded-spruce-biosciences-initiated-143317044.html

0 · Reply

Market Cap	80.12M
Revenue (ttm)	0.00
Net Income (ttm)	-38.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	33,200
Avg Vol	39,370
Day's Range	N/A - N/A
Shares Out	1.37M
Stochastic %K	19%
Beta	3.62
Analysts	Strong Sell
Price Target	$198.25